William Slayton, MD - Research

Research at a glance

Top areas of exploration

Hematopoietic Stem Cells , 12 publications
Bone Marrow Transplantation , 10 publications
Bone Marrow Cells , 9 publications
Hematopoietic Stem Cell Transplantation , 8 publications

Research activity

86 publications

2,301 citations

Why is this important?

Active clinical trials

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in P

This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common鈥�

Investigators: Brian Stover, William Slayton
Status: Accepting Candidates
Ages: 2 Years - 25 Years
Sexes: All

A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment o

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after鈥�

Investigators: Brian Stover, William Slayton
Status: Accepting Candidates
Ages: N/A - 22 Years
Sexes: All

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL)

The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin鈥�

Investigator: William Slayton
Status: Accepting Candidates
Ages: 3 Years - 39 Years
Sexes: All

My publications

86 publications

2014

Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.

International journal of radiation oncology, biology, physics

鈥�

2014

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

Leukemia

鈥�

2014

Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031.

Leukemia

鈥�

2013

Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans.

PloS one

鈥�

2013

Molecular mechanisms of platelet and stem cell rebound after 5-fluorouracil treatment.

Experimental hematology

鈥�

网红黑料